PolyPid Ltd stock (US70450B1035): pivotal Phase 3 data and Nasdaq listing shift in focus

PolyPid has reported new Phase 3 data for its lead surgical infection candidate D-PLEX100 and moved its listing from Nasdaq to the OTC market, reshaping the risk profile for investors.

PolyPid Ltd is back in focus after a series of late?stage clinical updates and capital market moves around its lead product candidate D?PLEX100, an extended?release antibiotic for surgical site infection prevention. Recent regulatory interactions and the transition of the company’s shares from Nasdaq to the OTC market are drawing renewed scrutiny from investors, according to updates on the company’s investor relations website and regulatory filings published in 2024 and early 2025, as reported by PolyPid investor relations as of 03/15/2025.

According to company disclosures on its website, PolyPid has been advancing D?PLEX100 through Phase 3 development for abdominal colorectal surgery and has communicated top?line results and follow?up analyses over the past year, while also adjusting its financing strategy after receiving Nasdaq deficiency notices related to minimum bid price and shareholders’ equity requirements, as described by Nasdaq / SEC filings as of 11/20/2024.

As of: 05/17/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: PolyPid Ltd
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Petach Tikva, Israel
• Core markets: Hospital surgical care and infection prevention
• Key revenue drivers: Potential commercialization of D?PLEX100 and other depot?based anti?infective therapies
• Home exchange/listing venue: OTC market in the US (formerly Nasdaq)
• Trading currency: USD

PolyPid Ltd: core business model

PolyPid focuses on developing extended?release, locally administered antibiotic formulations designed to prevent surgical site infections. The company’s technology platform combines biodegradable polymers with active pharmaceutical ingredients to create drug depots that release antibiotics over several days or weeks directly at the surgical site, according to a company description in its annual report filed in April 2024, cited by SEC Form 20?F as of 04/15/2024.

The lead candidate D?PLEX100 (also referred to as PolyPid’s lead product for infection prevention) targets the reduction of surgical site infections in colorectal abdominal procedures. In this setting, patients face significant infection risk despite systemic prophylactic antibiotics, and local sustained release may offer an additional layer of protection by maintaining higher local antibiotic concentrations while limiting systemic exposure, as outlined in the risk and business overview sections of the same 20?F filing, according to SEC Form 20?F as of 04/15/2024.

Beyond its core colorectal indication, PolyPid has discussed potential additional surgical applications for its technology, including orthopedic and other soft?tissue procedures where postoperative infection carries high complication and cost burdens. However, most of these applications remain at an earlier stage of development, and the company continues to allocate the majority of resources to D?PLEX100 clinical and regulatory workstreams, based on its pipeline tables and R&D expense breakdown in filings around 2023 and 2024, according to PolyPid investor presentation archive as of 09/10/2024.

Main revenue and product drivers for PolyPid Ltd

The potential future revenue narrative around PolyPid is centered almost entirely on D?PLEX100 reaching approval and market uptake in major regions such as the United States and Europe. In its 2023 Form 20?F, the company emphasized that it has not generated product revenues to date and remains dependent on external financing to fund development activities, highlighting the binary nature of its clinical and regulatory milestones, as disclosed by SEC Form 20?F as of 04/15/2024.

According to company updates, PolyPid completed at least one Phase 3 trial for D?PLEX100 in colorectal surgery and subsequently performed additional analyses and interactions with regulators to clarify the path toward a potential marketing application. These steps included reporting top?line efficacy and safety data, evaluating predefined subgroups and endpoints, and considering potential protocol adjustments or additional studies required by agencies, as indicated in press releases and conference call remarks summarizing Phase 3 outcomes released in 2023 and 2024, referenced by PolyPid news releases as of 10/30/2024.

To support these clinical and regulatory programs, PolyPid has repeatedly turned to the capital markets with equity offerings and warrant structures. The company reported net losses driven primarily by R&D and general and administrative expenses, and stated that existing cash, cash equivalents and deposits would not be sufficient to fund operations for an extended period without additional financing, according to its 2023 annual report and subsequent interim updates on liquidity, as summarized by SEC Form 20?F as of 04/15/2024.

Potential future product revenues would likely be influenced by the level of adoption among surgeons and hospitals, pricing relative to competing infection prevention strategies, reimbursement conditions in the US and Europe, and the ability to expand label indications beyond the initial colorectal focus. Because the company is still pre?revenue, investors often track proxy indicators such as partnering activity, licensing discussions or non?dilutive funding opportunities, which PolyPid’s management has mentioned as strategic priorities in various investor presentations across 2023 and 2024, according to PolyPid investor presentation archive as of 09/10/2024.

Industry trends and competitive position

PolyPid operates in the broader hospital infection prevention and anti?infective market, where antimicrobial resistance and rising healthcare costs have pushed providers to seek more effective methods to control surgical site infections. Large pharmaceutical and medical device companies market systemic antibiotics, antibiotic?impregnated materials and other adjunctive therapies, creating a competitive landscape that any new product must navigate in terms of clinical differentiation and cost?effectiveness, as discussed in the competitive landscape section of the company’s 2023 annual report, according to SEC Form 20?F as of 04/15/2024.

In filings, PolyPid acknowledges that several established players possess extensive sales networks, funding and manufacturing scale. However, the company argues that its depot technology could address unmet needs in specific high?risk surgeries by delivering antibiotics directly to the wound site over a prolonged period. If clinical data ultimately confirm meaningful reductions in infection rates or reoperations, such localized approaches might carve out a niche within standard of care protocols, especially in complex colorectal and orthopedic cases, based on the company’s positioning statements in investor materials dated 2023 and 2024, cited by PolyPid investor presentation archive as of 09/10/2024.

Sector?wide, regulators and payers have been increasingly attentive to value?based healthcare metrics. Technologies that can demonstrate lower rates of postoperative complications, shorter hospital stays and fewer readmissions may find receptive audiences among hospital administrators. PolyPid’s ability to present robust health?economic data, beyond pure clinical endpoints, could therefore be a key factor in its eventual competitive positioning if D?PLEX100 reaches commercialization, a point highlighted in management commentary during conference calls and webcasts in 2024, according to PolyPid events and presentations as of 12/05/2024.

Why PolyPid Ltd matters for US investors

Despite being headquartered in Israel, PolyPid’s primary commercial focus has been the US market, where colorectal surgery volumes and reimbursement structures create a potential addressable market for surgical site infection prevention tools. The company’s shares trade in US dollars on the OTC market after a prior Nasdaq listing, giving US investors direct access to the equity even though the operating base is outside the United States, as indicated in listing disclosures and investor FAQs, according to PolyPid investor relations as of 03/15/2025.

Regulatory outcomes in the US are particularly important because the Food and Drug Administration’s decisions can shape the potential for reimbursement and adoption in American hospitals. PolyPid has previously highlighted interactions with the FDA regarding trial design, endpoints and safety assessments for D?PLEX100, and has indicated that any future marketing application will be heavily dependent on robust Phase 3 data packages and alignment with regulators on benefit?risk considerations, as noted in its regulatory risk factor disclosures in 2023 and 2024, according to SEC Form 20?F as of 04/15/2024.

From a portfolio construction standpoint, US investors often categorize PolyPid as a high?risk, development?stage biotech exposure with binary event risk around clinical and regulatory milestones. In this context, movements in the share price can be significant when new data or financing terms are announced, and liquidity considerations on the OTC venue may add further volatility compared with larger, more diversified pharmaceutical stocks. These characteristics make careful monitoring of company announcements and filings particularly relevant for investors with exposure to the name, as highlighted in market commentary around PolyPid’s capital raises and listing changes in 2024, according to Nasdaq market activity overview as of 11/20/2024.

Risks and open questions

Key risks for PolyPid include clinical uncertainty around D?PLEX100, potential regulatory hurdles, and the company’s reliance on external capital. In its 2023 Form 20?F, management explicitly warned that failure to achieve positive clinical outcomes or obtain regulatory approvals on a timely basis could force the company to scale back operations, pursue strategic alternatives or, in an adverse scenario, cease operations, according to SEC Form 20?F as of 04/15/2024.

Financing risk is another central factor. PolyPid has historically funded operations through equity and warrant offerings that can dilute existing shareholders. Market conditions for small?cap biotech financing can fluctuate rapidly, and access to capital may be constrained if investor sentiment toward the sector weakens or if clinical timelines slip. The company has acknowledged that it may need to raise additional funds sooner than planned if costs rise or if partnerships do not materialize as expected, based on its liquidity discussion and subsequent financing announcements in 2024, as outlined by PolyPid news releases as of 10/30/2024.

There are also operational and competitive risks. Manufacturing scale?up for a depot?based antibiotic product must meet strict quality and consistency standards, while healthcare providers may be slow to change established prophylactic routines without compelling evidence and guidelines support. In addition, other companies are exploring alternative methods to reduce surgical site infections, including novel antibiotics, coated devices and non?antibiotic approaches, creating potential competition even if D?PLEX100 succeeds clinically, as noted in PolyPid’s discussion of competing technologies in its filings, according to SEC Form 20?F as of 04/15/2024.

Key dates and catalysts to watch

Looking ahead, investors are likely to focus on any future updates regarding regulatory feedback on D?PLEX100, potential additional analyses of Phase 3 data, and clarity on whether the company intends to submit a marketing application in major markets such as the United States or Europe. While specific upcoming meeting dates with regulators may not always be publicly disclosed in advance, PolyPid’s historical pattern has been to issue press releases around major milestones such as top?line data readouts, end?of?Phase meetings and strategic reviews, based on its 2023 and 2024 news flow, as compiled by PolyPid news releases as of 10/30/2024.

On the financial side, periodic reporting dates for annual and interim results, as well as announcements regarding capital raises or strategic collaborations, can serve as catalysts for the stock. The company typically files its annual Form 20?F in the second quarter of the calendar year and issues press releases in conjunction with financing transactions or partnership agreements. Monitoring the investor relations calendar and regulatory filings can therefore help investors stay abreast of developments that may influence the company’s cash runway, trial timelines and overall strategic direction, according to PolyPid events and presentations as of 12/05/2024.

Conclusion

PolyPid Ltd sits at a sensitive juncture where clinical, regulatory and financing decisions around D?PLEX100 will likely determine the company’s long?term trajectory. The extended?release antibiotic depot concept aims to address a clearly defined problem in colorectal and other high?risk surgeries, but success depends on robust late?stage data, constructive dialogue with regulators and eventual adoption by hospitals. For US?focused investors, the stock offers exposure to a targeted surgical infection prevention story, now trading on the OTC market and characterized by elevated event risk, significant volatility and a strong dependence on future capital access and partnership execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.